American Cancer Society Reverses Course, Urges Routine Prostate Cancer Screening
Health·November 13, 2026

The American Cancer Society has changed its guidance on prostate cancer screening. The group now urges routine testing for men aged 50 to 69 who are at average risk of the disease, and it recommends a prostate-specific antigen (PSA) blood test every two years for that group.
The change matters because prostate screening has been one of the most contested questions in cancer prevention for years. A PSA test can catch tumors early, but it also flags many slow-growing cancers that would never have caused harm. Those findings can lead to biopsies, treatment, and side effects such as urinary incontinence or erectile dysfunction. For that reason, several medical bodies have favored letting each patient weigh the trade-offs with a doctor instead of making screening a default. The U.S. Preventive Services Task Force, for example, has taken a more cautious line for men in this age range in recent years.
Average risk is the key phrase in the new recommendation. Men who face higher risk, including those with a close relative diagnosed at a young age, have historically been advised to start talking with their doctors earlier than age 50. Readers who fall into a higher-risk category should check the society's full guidance on how it applies to them, since the headline recommendation focuses on men at average risk.
For most men in the 50 to 69 range, the practical takeaway is to bring the question to a primary care doctor. The PSA test is a simple blood draw, but a result is only one piece of the picture. A raised PSA level does not on its own mean cancer is present, and doctors typically interpret it alongside age, family history, and other test results before deciding whether further evaluation is needed.
Reporting based on an external source.